ACQ2 by Acquired cover art

ACQ2 by Acquired

By: Ben Gilbert and David Rosenthal
  • Summary

  • ACQ2 is Ben and David's conversations with expert founders and investors. Acquired the stories of great companies — and ACQ2 dives deeper into the lessons we can learn from them, often with the protagonists themselves.
    Copyright 2019-2023 ACQ, LLC
    Show More Show Less
Episodes
  • The Software Behind Silicon (with Synopsys Founder Aart de Geus and CEO Sassine Ghazi)
    May 6 2024

    If you’ve been waiting for us to venture back to the land of semiconductors, you’re in luck! On our NVIDIA and TSMC episodes, we explored two components of the silicon value chain: the fabless chip companies that design chips and the foundries that manufacture them. Today, we dive into the software that powers it all, the field electronic design automation (EDA). This is essentially the software that enables chip designers to do their jobs, which has changed dramatically with the rise of AI.

    This interview is with two people who understand that world better than anyone: Aart de Geus, the co-founder and Executive Chair of Synopsys, and Sassine Ghazi, Synopsys’s CEO and President. Aart founded the company in 1986, and was CEO until January 2024 when he handed the reins to Sassine. Synopsys is now worth $80 billion, with virtually every chip company as a customer or partner for everything from AI to 5G to automotive. Aart and Sassine talked with us about the future Moore’s Law, where chip makers are finding efficiencies today, how we got here, plus a bonus section on simulation and their $35 billion acquisition of Ansys. Enjoy!

    Sponsors:

    • Quartr

    Show More Show Less
    1 hr and 16 mins
  • The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
    Mar 6 2024

    On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:

    • The science behind what is happening in the body that causes weight loss while on Ozempic
    • What it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written off
    • How weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!

    Sponsors:

    • Quartr

    Show More Show Less
    1 hr and 1 min
  • Visa Follow-Up and Today’s Payments Ecosystem (with Gaurav Ahuja)
    Dec 3 2023

    We’re joined by Imprint cofounder and Thrive General Partner Gaurav Ahuja to dive deeper into the modern payments ecosystem and Visa’s current place within it. Gaurav was one of our research sources for the Visa episode, and we wanted to bring his insights to you all too. We discuss whether Visa really should be worried about eroding interchange fees, the impact of realtime payments systems, opportunities for startups and whether the Visa / Mastercard duopoly could really be overthrown. Tune in and enjoy!


    Links:

    • https://www.federalreserve.gov/paymentsystems/files/Avg_IF_by_PCN.pdf

    Sponsors:

    • Quartr

    Show More Show Less
    1 hr and 35 mins

More from the same

Author

What listeners say about ACQ2 by Acquired

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.